QuotedData

Quoted Data

sign up for emailed equity research
Quick  |   Customised Register
Latest News

Biotech and Healthcare News

WPCT set to record £33m gain on Sensyne Health

WPCT set to record £33m gain on Sensyne Health

WPCT set to record £33m gain on Sensyne Health IPO Woodford Patient Capital Trust (WPCT) looks set to record a £33m gain and a 45x return on its original shareholding in ...

BG-backed Orchard raises $150m on the back of GSK deal

BG-backed Orchard raises $150m on the back of GSK deal

BG-backed Orchard raises $150m on the back of GSK deal Baillie Gifford-backed US-UK gene therapy company Orchard Therapeutics has raised $150m in a Series C financing  just four months after acquiring GlaxoSmithKline’s ...

Alnylam receives expected FDA ok for Onpattro

Alnylam receives expected FDA ok for Onpattro

Alnylam receives expected FDA ok for Onpattro Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq: ALNY) received its  first FDA approval late on Friday for Onpattro (patisiran) for the treatment of polyneuropathy ...

FDA sets Feb target review date for IBT-backed Stemline Therapeutics

FDA sets Feb target review date for IBT-backed Stemline Therapeutics

FDA sets Feb target review date for IBT-backed Stemline Therapeutics The US FDA has accepted  Stemline Therapeutics (Nasdaq:STML)'s filing for Elzonris (tagraxofusp) for review for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ...

Woodford finally closes chapter on failed Vernalis investment

Woodford finally closes chapter on failed Vernalis investment

Woodford finally closes chapter on failed Vernalis investment Neil Woodford's eponymous Patient Capital Trust (WPCT) will have to look forward to receiving just £1.8m for the 30.6m shareholding - acquired in 2015 ...

Syncona remains at high premium and highly geared to Autolus

Syncona remains at high premium and highly geared to Autolus

Syncona remains at high premium and highly geared to Autolus Syncona's shares have been the second best performer this year among the 14 biotech investment trusts monitored by Marten & Co, ...

Arix-backed Artios completes £65m fundraising

Arix-backed Artios completes £65m fundraising

Arix-backed Artios completes £65m fundraising  Artios Pharma, the Cambridge-based biotech backed by LSE-listed venture firm Arix Bioscience (ARIX), has completed a £65m Series B financing, allowing it to advance its lead ...

Trust favourite Alnylam approaches key FDA decision

Trust favourite Alnylam approaches key FDA decision

Trust favourite Alnylam approaches key FDA decision Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq:ALNY) should find out later this week whether the FDA will grant approval to its first product, Onpattro (patisiran), ...

IBT backed Regeneron teams up with Bluebird on T cell cancer therapies

IBT backed Regeneron teams up with Bluebird on T cell cancer therapies

IBT backed Regeneron teams up with Bluebird on T cell cancer therapies US top tier biotech Regeneron Pharmaceuticals (NASDAQ: REGN) is to make a $100m equity investment at a 59% premium in ...

Arix leads first VIPE into Pharmaxis

Arix leads first VIPE into Pharmaxis

Arix leads first VIPE into Pharmaxis LSE-quoted life science investor Arix Bioscience (ARIX) is to acquire an 11% interest in Pharmaxis (ASX: PXS) in its first VIPE or venture investment in ...

Contact us

captcha